8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one manufacturers
|
| | 8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one Basic information |
| Product Name: | 8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one | | Synonyms: | Palbociclib-021;Palbociclib-3;Palbociclib impurity 22/8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl) amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one;Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-cyclopentyl-6-ethenyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-;8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride;Palbociclib Impurity 77 0.7HCl 0.3HCOOH;Palbociclib EP Impurity-G;Desoxo-palbociclib HCl/8-Cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride | | CAS: | 2204863-06-7 | | MF: | C24H29N7O | | MW: | 431.53 | | EINECS: | | | Product Categories: | | | Mol File: | 2204863-06-7.mol | ![8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one Structure](CAS/20200331/GIF/2204863-06-7.gif) |
| | 8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one Chemical Properties |
| Boiling point | 672.3±65.0 °C(Predicted) | | density | 1.306±0.06 g/cm3(Predicted) | | solubility | DMSO (Very Slightly, Heated) | | pka | 8.66±0.10(Predicted) | | form | Solid | | color | Light Yellow | | InChIKey | BAMRZESJXFABIT-UHFFFAOYSA-N | | SMILES | C1(NC2=NC=C(N3CCNCC3)C=C2)=NC=C2C(C)=C(C=C)C(=O)N(C3CCCC3)C2=N1 |
| | 8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one Usage And Synthesis |
| Uses | Desoxo-palbociclib is a derivative compound of Palbociclib (P139900). Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. |
| | 8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one Preparation Products And Raw materials |
|